CD Biosynsis offers advanced HeLa Cells-Based Assay and Modeling Services, combining high-resolution experimental data with predictive computational tools to accelerate biomedical research. HeLa cells, the most well-characterized human cancer cell line, serve as a premier platform for studying human physiology, oncology, and pharmacology. Our services bridge the gap between simple cell culture and complex disease modeling by integrating High-Throughput Screening (HTS), Multiplex Assays, and Systems Biology Modeling. We help researchers quantify cellular responses to drugs, viral infections, and genetic modifications, providing deep insights into the systemic behavior of human cell networks.
Get a QuoteModern drug discovery and functional genomics require more than just end-point observations. Our HeLa platform utilizes a "Data-to-Model" approach where high-quality experimental assays provide the parameters needed for predictive simulations. By characterizing the hyper-triploid HeLa genome's unique metabolic and signaling signatures, we create models that can predict how human cells will respond to external stimuli or internal genetic changes. This integrated workflow is essential for identifying drug mechanisms of action, optimizing viral vector production, and understanding complex signaling crosstalk in cancer.
Cytotoxicity & Proliferation
High-throughput screening of drug candidates using MTT, CCK-8, or real-time impedance-based monitoring to quantify growth inhibition and IC50 values.
Cell Death Analysis
Quantitative detection of apoptosis, necrosis, and autophagy via Flow Cytometry (Annexin V/PI) and high-content imaging of mitochondrial membrane potential.
Migration & Invasion
Quantifying cancer cell dynamics using wound healing (scratch) assays and Transwell invasion assays to evaluate anti-metastatic drug efficacy.
Transcriptomics & qPCR
RNA-Seq and high-throughput qPCR to measure gene expression profiles post-treatment or post-genetic modification (KO/KI).
Metabolomics
LC-MS/MS analysis of intracellular metabolites to map the unique energy landscape of HeLa cells, identifying metabolic bottlenecks and byproduct accumulation.
Proteomics
Quantifying total protein expression and phosphorylation states (phospho-proteomics) to monitor signaling network activity.
Reporter Assays
Utilizing stable HeLa reporter lines (Luciferase, GFP) to quantify the activation of NF-kappaB, p53, or other regulatory pathways in real-time.
Viral Entry & Replication
Assaying viral attachment, internalization, and replication efficiency using modified HeLa strains to study host-pathogen interactions.
We use assay data to parameterize and validate advanced human cell models, providing a predictive framework for your research.
1. Metabolic Modeling (FBA)
2. Signaling Network Modeling
3. Pharmacodynamic (PD) Modeling
4. Multi-Omics Integration
Utilizing Genome-Scale Metabolic Models (GEMs) adapted for HeLa's aneuploid genome.
Performing Flux Balance Analysis (FBA) to predict growth rates, nutrient consumption, and the impact of metabolic gene knockouts.
Building kinetic models of key signaling pathways (e.g., MAPK, PI3K/AKT) to simulate signal propagation and crosstalk.
Predicting the impact of single-nucleotide polymorphisms (SNPs) or targeted drugs on pathway flux and cellular decision-making.
Integrating transcriptomic and proteomic data into a unified cellular map to identify master regulators of specific phenotypes.
Virtual screening of genetic targets to prioritize those most likely to yield the desired experimental outcome.
High-Throughput Scale
Our automated assay platforms allow for the rapid screening of thousands of conditions, providing the large datasets necessary for robust modeling.
Human System Fidelity
HeLa cells provide a relevant human metabolic and signaling background, making predictions more applicable to human biology than animal-derived lines.
Predictive Power
Our computational models allow you to perform "in silico" experiments, prioritizing the most promising targets and reducing laboratory "trial and error."
Aneuploidy-Aware Analysis
We specifically account for the extra chromosomal copies in HeLa cells, ensuring that our assays and models reflect the true genetic dosage of the line.
1. Can you model drug resistance in HeLa cells?
Yes. By assaying drug-resistant HeLa variants and comparing their omics profiles with sensitive lines, we can build models that identify the specific metabolic or signaling shifts responsible for resistance.
2. What is Flux Balance Analysis (FBA)?
FBA is a mathematical approach used to simulate the flow of metabolites through a metabolic network. It allows us to predict how a cell's growth or production of specific molecules will change when certain genes are knocked out.
3. Do you provide raw data or interpreted reports?
We provide both. You will receive all raw experimental data (e.g., flow cytometry plots, sequencing reads) along with a comprehensive modeling report that translates the data into biological insights.
4. How long does a typical integrated assay and modeling project take?
Timelines vary based on complexity, but a standard project involving HTS screening and initial metabolic modeling typically takes 8 to 12 weeks.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.